NeonMind Announces Consolidation
Jan 19, 2023
January 19, 2023 Oakville, Ontario – January 19, 2023: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in
Clear Minds,
Bright Future
Advancing Psychedelic Science to Tackle Obesity, Mental Health, and Wellness
NeonMind Biosciences Inc., is an integrated psychedelic drug development and wellness company focused on the therapeutic uses of psychedelics to address public health needs including obesity, weight management and mental health. At NeonMind Biosciences, we believe in “mind over matter” with the ultimate goal of supporting human health through our psychedelic drug development program and NeonMind-branded specialty mental health clinics.
Harnessing Psychedelic Medicine Through Evidence and Science
In our pharmaceutical division, we are developing the first and only novel psilocybin-based drug candidates targeting obesity, a global health issue and one of the leading causes of death. Integral to the adoption of psychedelic medicine is the deployment of medical treatment services. NeonMind has established a medical services division which will be launching specialty mental health clinics in Canada that incorporate innovative, evidence-backed validated interventional psychiatry treatments for mood and anxiety disorders, a leading cause of disability in our society. Our goal is to help patients with weight management and mental health issues.
Our Dual Approach to Psychedelic Medicine
We are advancing psychedelic medicine and therapeutic treatments to improve bodies and minds through our two operating divisions.
Pharmaceutical Division
Targeting Obesity with Revolutionary Psychedelic Compounds
NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional drug candidate, NEO-002, which employs low-dose psilocybin to control appetite. In addition, the Company has extensive U.S. and international patent applications pending which cover a wide spectrum of weight management conditions.
Medical Services Division
Enhancing Access to Specialized Interventional Psychiatry Treatments through NeonMind Clinics
Our medical services division is preparing to launch NeonMind-branded specialty mental health clinics across Canada, offering evidence-backed validated interventional psychiatry treatments tailored to local market needs. The Company has built a leading scientific advisory board, globally renowned for their expertise in practicing interventional psychiatry to treat mood and anxiety disorders. A medical services platform entrenched in the growing psychedelic sector, by improving access to validated treatments and incorporating the promising pipeline of psychedelic treatments as they are approved.
NeonMind Announces Cancellation of Securities
Jan 11, 2023
January 11, 2023 Oakville, Ontario – January 11, 2023: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for the
NeonMind Signs Agreement to complete Reverse Merger with Lancaster Lithium Inc.
Dec 14, 2022
December 14, 2022 Oakville, Ontario – December 14, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) is pleased to announce that it
Email Alerts
Stay informed and receive company updates straight to your inbox.
English